Gemina Laboratories Ltd
CNSX:GLAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Gemina Laboratories Ltd
Net Income (Common)
Gemina Laboratories Ltd
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Gemina Laboratories Ltd
CNSX:GLAB
|
Net Income (Common)
-CA$4.1m
|
CAGR 3-Years
5%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
B
|
BioMark Diagnostics Inc
CNSX:BUX
|
Net Income (Common)
-CA$1.7m
|
CAGR 3-Years
6%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
MedMira Inc
XTSX:MIR
|
Net Income (Common)
-CA$3.5m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-1%
|
|
Gemina Laboratories Ltd
Glance View
Gemina Laboratories Ltd. (Gemina) is a Canada-based biotechnology company. Gemina operates in the In Vitro Diagnostics (IVD) and human wellness monitoring market under the name Gemina Labs. It is engaged in biosensor and diagnostic services with a transformative, patented, proprietary chemistry that powers next-generation testing platforms for a wide range of pathogens that affect human health and wellness. Gemina's technology drives testing platforms that are fast, affordable and accurate, and easily self-administered. Its development pipeline includes platforms for the rapid testing of COVID-19, influenza and other viruses. Gemina is focused on infectious respiratory diseases and the recovery from them. It has developed a first-generation technology (the Generation 1 Technology), which it has included within an initial demonstration product namely: a point-of-care lateral flow assay to test whether a person is infected with COVID-19 (the Legio-XTM COVID Rapid Antigen Test).
See Also
What is Gemina Laboratories Ltd's Net Income (Common)?
Net Income (Common)
-4.1m
CAD
Based on the financial report for Jan 31, 2025, Gemina Laboratories Ltd's Net Income (Common) amounts to -4.1m CAD.
What is Gemina Laboratories Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
5%
Over the last year, the Net Income (Common) growth was 22%. The average annual Net Income (Common) growth rates for Gemina Laboratories Ltd have been 5% over the past three years .
